Galecto
As of the edition of 20 October 2026, Galecto runs 5 drugs; it is on route A at 1 target and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Galecto was renamed in 2026.
The records place 3 company names in this family.
- Galecto, Inc.: renamed in 2026
- PharmAkea, Inc.: acquired
Drugs by status
| Status | Count |
|---|---|
| Stopped | 3 |
| Status not established | 2 |
| Total | 5 |
Where it needs a new molecule
Route A at 1 target, route B at 0 targets.
| Target | Route |
|---|---|
| LOXL2 Lysyl oxidase homolog 2 | Route A |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Galecto needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Digestive system: 3 trials led
- Blood and lymph: 2 trials led
- Cancer: 2 trials led